(NYSEMKT: AEON) Aeon Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Aeon Biopharma's earnings in 2025 is -$3,000.On average, 4 Wall Street analysts forecast AEON's earnings for 2025 to be -$8,150,771, with the lowest AEON earnings forecast at -$8,005,158, and the highest AEON earnings forecast at -$8,204,044. On average, 3 Wall Street analysts forecast AEON's earnings for 2026 to be -$8,452,651, with the lowest AEON earnings forecast at -$8,121,175, and the highest AEON earnings forecast at -$8,701,259.
In 2027, AEON is forecast to generate -$5,071,591 in earnings, with the lowest earnings forecast at -$4,872,705 and the highest earnings forecast at -$5,220,755.